Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.
Try us for 14 days
Try a trial subscription for access to our quality journalism
Danish biotech boss after shelved Lilly project: "We have better molecules"
Eli Lilly has interrupted the development of an experimental diabetes drug licensed in from a subsidiary of Danish Nordic Bioscience. According to CEO in Nordic Bioscience, Morten Karsdal, there are better molecules to develop in the partnership.
ADVERTISEMENT
